Pfizer to Acquire Biohaven Pharmaceutical for $11.6 Billion

Source: Yahoo! News

“Pfizer Inc. said it will acquire Biohaven Pharmaceutical Holding Co. for $11.6 billion in cash to gain an approved treatment for migraine headaches. Pfizer will pay $148.50 a share for all of New Haven, Connecticut-based Biohaven’s outstanding stock, according to a statement Tuesday. For each share of Biohaven, shareholders including Pfizer will also receive half a share of New Biohaven, a new publicly traded company that will retain some compounds in development that don’t use the anti-migraine technology, called CGRP. … Worldwide peak sales for Biohaven’s drug franchise could be over $6 billion a year, Pfizer executives said on a call with analysts Tuesday.” (05/10/22)